Tuberculosis treatment outcome monitoring in European Union countries: systematic review

Abstract

Treatment success measured by treatment outcome monitoring (TOM) is a key programmatic output of tuberculosis (TB) control programmes. We performed a systematic literature review on national-level TOM in the 30 European Union (EU)/European Economic Areas (EEA) countries to summarise methods used to collect and report data on TOM.Online reference bibliographic databases PubMed/MEDLINE and EMBASE were searched to identify relevant indexed and non-indexed literature published between January 2000 and August 2010.The search strategy resulted in 615 potentially relevant indexed citations, of which 27 full-text national studies (79 data sets) were included for final analysis. The selected studies were performed in 10 EU/EEA countries and gave a fragmented impression of TOM in the EU/EEA. Publication year, study period, sample size, databases, definitions, variables, patient and outcome categories, and population subgroups varied widely, portraying a very heterogeneous picture.This review confirmed previous reports of considerable heterogeneity in publications of TOM results across EU/EEA countries. PubMed/MEDLINE and EMBASE indexed studies are not a suitable instrument to measure representative TOM results for the 30 EU/EEA countries. Uniform and complete reporting to the centralised European Surveillance System will produce the most timely and reliable results of TB treatment outcomes in the EU/EEA.

Factors Associated with Unfavorable Treatment Outcomes in New and Previously Treated TB Patients in Uzbekistan: A Five Year Countrywide Study

“…Systematic reviews have highlighted that there are limited large-scale data on TB treatment outcomes. Another systematic review of national-level TB treatment outcomes among the 30 European Union /European Economic Area countries indicated the same [9]. The WHO Global TB Report provide such data at national level; however detailed analysis of individual patient data, as well as associations between unfavorable treatment outcomes and selected demographic and clinical characteristics, are not reported [5].…”

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

“…Further analyses have shown that if patients fail to achieve sputum culture conversion (SCC) from growth of MTB to no growth of MTB early in the course of MDR-TB treatment, they have a much higher likelihood of a poor outcome at the end of treatment, including death [8, 9]. Even in high resource settings such as the European Union (EU), surveillance data showed that treatment success averaged from 30–49% for 2007–2008 MDR-TB cohorts [10, 11], although under reporting of treatment outcomes may have affected these results [12]. …”

Legionnaires' disease in Europe: all quiet on the eastern front?

“…Infectious disease surveillance is an import tool in detecting unusual events, assessing trends and monitoring the impact of programmes [15][16][17][18][19][20][21][22][23]. Legionnaires' disease is notifiable in all 27 European Union countries, plus Iceland and Norway.…”